Augmedix

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Healthcare professionals, marketers and institutions spend nearly 40 per cent of their time creating and publishing content, which diverts resources from patient care, research and innovation.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

To tackle data-retrieval-based hallucinations in non-diagnostic use cases, Mayo Clinic has applied CURE reverse RAG paired with vector databases.

Medical errors are the third leading cause of death in the U.S., contributing to over 250,000 preventable deaths each year. NeuralCure AI is tackling this crisis head-on by eliminating diagnostic blind spots and accelerating treatment precision with its cutting-edge AI-driven decision support system.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

In an era of rapid technological advancements, the fusion of Augmented Reality (AR) and Artificial Intelligence (AI) is revolutionizing healthcare. These innovations enhance medical workflows, improve surgical precision,